Comparing Octreotide vs Pegvisomant
| Octreotide | Pegvisomant |
|
|---|
| Octreotide | Pegvisomant |
|
|||||||
|---|---|---|---|---|---|---|---|---|---|
|
Prescription only
Prescribed for Carcinoid Tumor, Diarrhea, Acromegaly, Diabetes - Type 1, Vasoactive Intestinal Peptide Tumor, Dumping Syndrome, Gastrinoma, Glucagonoma, Insulinoma, Pituitary Adenoma, Postural... View more |
Prescription only
Prescribed for Acromegaly. Pegvisomant may also be used for purposes not listed in this medication guide. |
Related suggestions Popular comparisons
|
|||||||
| More about Octreotide | More about Pegvisomant | ||||||||
| Ratings & Reviews | |||||||||
|
Octreotide has an average rating of 7.8 out of 10 from a total of 19 ratings on Drugs.com. 74% of reviewers reported a positive effect, while 11% reported a negative effect. |
Pegvisomant has an average rating of 5.8 out of 10 from a total of 4 ratings on Drugs.com. 50% of reviewers reported a positive effect, while 50% reported a negative effect. |
||||||||
| Side Effects Experienced by Users Side effects are reported in Drugs.com user reviews and not clinically verified. | |||||||||
|
View all Octreotide side effects |
View all Pegvisomant side effects |
||||||||
| Drug Class | |||||||||
| Generic Availability | |||||||||
|
Lower cost generic |
N/A |
||||||||
| Pricing and Coupons * Prices are without insurance | |||||||||
View all Octreotide prices |
We could not find an exact match for this medicine. Try searching the Price Guide directly. |
||||||||
| Dosage Forms | |||||||||
|
N/A |
||||||||
| Brand Names | |||||||||
| Bynfezia Pen, Mycapssa, Sandostatin, Sandostatin LAR Depot | Somavert | ||||||||
| Half Life Drug half-life is the time required for plasma concentration to reduce to half its original value. | |||||||||
|
1.5 hours |
144 hours |
||||||||
| CSA Schedule 1 View glossary of CSA terms | |||||||||
|
Not a controlled drug
Is not subject to the Controlled Substances Act. |
Not a controlled drug
Is not subject to the Controlled Substances Act. |
||||||||
| Pregnancy Category | |||||||||
|
Category B
No proven risk in humans
See the full pregnancy warnings document. |
Category B
No proven risk in humans
See the full pregnancy warnings document. |
||||||||
| Drug Interactions | |||||||||
|
A total of 167 drugs are known to interact with Octreotide:
|
A total of 74 drugs are known to interact with Pegvisomant:
|
||||||||
| Alcohol/Food/Lifestyle Interactions | |||||||||
|
No known alcohol/food interactions. This does not necessarily mean no interactions exist. Always consult your healthcare provider. |
||||||||
| Disease Interactions | |||||||||
| First Approval Date | |||||||||
|
June 26, 2020 |
N/A |
||||||||
| WADA Class View classifications | |||||||||
|
N/A |
N/A |
||||||||
| More Information | |||||||||
| Patient Resources | |||||||||
| Professional Resources | |||||||||
| Related Treatment Guide | |||||||||
1 The Controlled Substances Act (CSA) schedule information displayed applies to substances regulated under federal law. There may be variations in CSA schedules between individual states.
See also:
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.